|1.||Kuriyama, Hiroshi: 2 articles (02/2008 - 01/2007)|
|2.||Kajiki, Masahiro: 2 articles (02/2008 - 01/2007)|
|3.||Kobayashi, To-ru: 1 article (02/2008)|
|4.||Sugahara, Shu-ichi: 1 article (02/2008)|
|5.||Kobayashi, To-Ru: 1 article (01/2007)|
|6.||Sugahara, Shu-Ichi: 1 article (01/2007)|
01/22/2007 - "Pharmacokinetic studies showed that there were significant increases in the amount and the exposure time of total paclitaxel in the tumors after intravenous administration of AZ10992, which explains the enhanced efficacy of AZ10992."
01/22/2007 - "Additionally, the comparative efficacy studies of AZ10992 and paclitaxel using a panel of human tumor xenografts in nude mice showed the advantages of drug-polymer conjugation. "
02/01/2008 - "AZ10992 is a novel paclitaxel-carboxymethyl (CM) dextran conjugate via a Gly-Gly-Phe-Gly linker with the molecular weight (MW) of 150 kDa. Our previous studies demonstrated that AZ10992 exerts strong antitumor activity against the human tumor xenografts that are highly refractory to paclitaxel, attributable to passive tumor targeting of released paclitaxel. "
01/22/2007 - "The in vivo antitumor study using AZ10992 against colon26 carcinoma cells, resistant to paclitaxel, supported this concept. "
01/22/2007 - "A repeated intravenous administration of AZ10992 at 30 mg/kg/day (five injections for 4-days) showed complete regression of MX-1 mammary carcinoma xenografts. "
01/22/2007 - "Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992)."
|3.||Colorectal Neoplasms (Colorectal Cancer)
|5.||K 76 carboxylic acid
|1.||Heterologous Transplantation (Xenotransplantation)